drugset / Trial / NCT07109726
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.
Timeline
- Start
- 2025-09-23
- Primary completion
- 2028-12-30
- Completion
- 2029-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TER-2013 | Unknown | — | Oral |
| Background | Fulvestrant | Small molecule | 500 mg | Intramuscular |